Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBO-Seq trial in metastatic renal cell carcinoma
2025-523903-31-00Phase 3Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, ipilimumab, pembrolizumab, axitinib, lenvatinib and 3 more in renal cell carcinoma (RCC) (3 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoints: PFS-2 and Overall survival. Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2025-523903-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523903-31-00.